Literature DB >> 11798169

Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes.

Sho-ichi Yamagishi1, Shinjiro Amano, Yosuke Inagaki, Tamami Okamoto, Kohachiro Koga, Nobuyuki Sasaki, Hiroshi Yamamoto, Masayoshi Takeuchi, Zenji Makita.   

Abstract

The influence of advanced glycation end products (AGEs) on apoptotic cell death and vascular endothelial growth factor (VEGF) gene expression in cultured bovine retinal pericytes was investigated. When pericytes were incubated with three immunochemically distinct AGEs, which were prepared in vitro by incubating bovine serum albumin with glucose, glyceraldehyde, or glycolaldehyde, apoptotic cell death and DNA ladder formation were significantly induced. The cytopathic effects of glyceraldehyde- or glycolaldehyde-derived AGEs were significantly enhanced in AGE receptor-transfected pericytes. Furthermore, all of these AGEs were found to upregulate the secretory forms of VEGF mRNA levels in retinal pericytes. These results suggest that AGEs disturbed retinal microvascular homeostasis by inducing pericyte apoptosis and VEGF overproduction and thus were involved in the pathogenesis of early phase diabetic retinopathy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11798169     DOI: 10.1006/bbrc.2001.6312

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  49 in total

1.  High glucose induces mitochondrial morphology and metabolic changes in retinal pericytes.

Authors:  Kyle Trudeau; Anthony J A Molina; Sayon Roy
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

Review 2.  Trends in advanced glycation end products research in diabetes mellitus and its complications.

Authors:  José D Méndez; Jianling Xie; Montserrat Aguilar-Hernández; Verna Méndez-Valenzuela
Journal:  Mol Cell Biochem       Date:  2010-03-23       Impact factor: 3.396

3.  MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells.

Authors:  Yuhki Sakuraoka; Tokihiko Sawada; Toshie Okada; Takayuki Shiraki; Yoshikazu Miura; Katsuya Hiraishi; Tatsushi Ohsawa; Masakazu Adachi; Jun-ichi Takino; Masayoshi Takeuchi; Keiichi Kubota
Journal:  World J Gastroenterol       Date:  2010-11-14       Impact factor: 5.742

4.  Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation.

Authors:  Masahiko Yokoi; Sho-ichi Yamagishi; Masayoshi Takeuchi; Takanori Matsui; Yumiko Yoshida; Kazuhiro Ohgami; Tamami Amano-Okamoto; Shigeaki Ohno
Journal:  Br J Ophthalmol       Date:  2007-03       Impact factor: 4.638

5.  Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.

Authors:  W Todd Cade
Journal:  Phys Ther       Date:  2008-09-18

Review 6.  A role for pericytes in coronary no-reflow.

Authors:  Fergus M O'Farrell; David Attwell
Journal:  Nat Rev Cardiol       Date:  2014-04-29       Impact factor: 32.419

7.  Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells.

Authors:  Keiko Iwamoto; Keishi Kanno; Hideyuki Hyogo; Sho-Ichi Yamagishi; Masayoshi Takeuchi; Susumu Tazuma; Kazuaki Chayama
Journal:  J Gastroenterol       Date:  2008-05-06       Impact factor: 7.527

8.  The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity.

Authors:  Jun-ichi Takino; Yuka Kobayashi; Masayoshi Takeuchi
Journal:  J Gastroenterol       Date:  2010-01-19       Impact factor: 7.527

Review 9.  Too sweet: Problems of protein glycation in the eye.

Authors:  Eloy Bejarano; Allen Taylor
Journal:  Exp Eye Res       Date:  2018-08-24       Impact factor: 3.467

10.  Leukostasis and pigment epithelium-derived factor in rat models of diabetic retinopathy.

Authors:  Masato Matsuoka; Nahoko Ogata; Keizo Minamino; Miyo Matsumura
Journal:  Mol Vis       Date:  2007-06-29       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.